Skip to main content
Premium Trial:

Request an Annual Quote

FDA Approves Foundation Medicine Test as CDx With Roche's Rozlytrek

NEW YORK – Roche subsidiary Foundation Medicine announced on Thursday that its FoundationOne CDx test has been approved by the US Food and Drug Administration as a companion diagnostic with Roche's Rozlytrek (entrectinib). 

The test was approved by the FDA to identify patients with ROS1 fusion-positive non-small cell lung cancer or patients with NTRK fusion-positive solid tumors for whom treatment with Rozlytrek could be appropriate. It is the first and only FDA-approved CDx for this indication, Roche said in a statement. As a condition of the test's approval, Foundation will conduct a study to further demonstrate FoundationOne CDx's ability to identify patients with ROS1 fusion-mutated NSCLC who could potentially benefit from Rozlytrek.

Rozlytrek is a targeted therapy approved to treat ROS1 fusion-positive metastatic NSCLC and a tumor-agnostic medicine for locally advanced or solid tumors that have NTRK fusions. In 2019, the FDA granted accelerated approval to the drug as a treatment for adult and adolescent patients whose cancers have NTRK gene fusions and are out of treatment options, as well as for adults with metastatic non-small cell lung cancer whose tumors are ROS1-positive.

"The ability to tailor cancer therapies based on specific genomic alterations using validated comprehensive genomic profiling (CGP) has transformed the traditional 'one-size fits-all' approach to cancer," Levi Garraway, Roche's chief medical officer and head of global product development, said in a statement. "This approval marks a significant step forward in expanding treatment options and improving outcomes for patients, particularly those with rare tumors."

The Scan

Monkeypox Meeting

As the World Health Organization gets ready to hold another monkeypox meeting, the US distributes vaccines and increases its testing capacity.

CRISPR's Softer Side

A homologous chromosome-templated repair approach to gene editing relies on versions of the Cas9 enzyme that cut a single DNA strand.

Pickled? No Problem

Researchers come up with an approach for extracting DNA from archived museum specimens. 

Nature Papers on Long Reads for Bacterial Genomes, Zebrafish Atlas, Hypothalamic Aging in Mammals

In Nature this week: near-finished microbial genomes without polishing, zebrafish functional annotation program, and more.